Pazufloxacinの臨床的検討

書誌事項

タイトル別名
  • Clinical study of pazufloxacin

この論文をさがす

抄録

We evaluated the clinical efficacy and safety of pazufloxacin (PZFX), a new quinolone antimicrobial agent. PZFX was administrated to 11 patients with infections. The patients received the drug, orally, for 3 to 14 days at a dose of 200-600 mg/day.<BR>Clinical effects were good in ten cases and unevaluable in one case. No side effects or abnormal laboratory findings were observed.

収録刊行物

参考文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ